Mosaic Family Wealth LLC Has $274,000 Stake in Sarepta Therapeutics Inc (NASDAQ:SRPT)

Mosaic Family Wealth LLC lifted its position in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 21.1% during the first quarter, HoldingsChannel.com reports. The firm owned 2,300 shares of the biotechnology company’s stock after acquiring an additional 400 shares during the period. Mosaic Family Wealth LLC’s holdings in Sarepta Therapeutics were worth $274,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. TIAA CREF Investment Management LLC grew its stake in Sarepta Therapeutics by 35.5% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 281,890 shares of the biotechnology company’s stock valued at $45,528,000 after acquiring an additional 73,792 shares during the period. Vanguard Group Inc grew its stake in Sarepta Therapeutics by 3.3% in the 3rd quarter. Vanguard Group Inc now owns 5,384,899 shares of the biotechnology company’s stock valued at $869,715,000 after acquiring an additional 170,999 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in Sarepta Therapeutics in the 4th quarter valued at $51,000. Advisors Asset Management Inc. grew its stake in Sarepta Therapeutics by 15.7% in the 4th quarter. Advisors Asset Management Inc. now owns 3,473 shares of the biotechnology company’s stock valued at $379,000 after acquiring an additional 470 shares during the period. Finally, SG Americas Securities LLC grew its stake in Sarepta Therapeutics by 230.2% in the 4th quarter. SG Americas Securities LLC now owns 4,950 shares of the biotechnology company’s stock valued at $540,000 after acquiring an additional 3,451 shares during the period.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the firm’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $120.00, for a total value of $1,200,000.00. Following the transaction, the director now owns 21,717 shares in the company, valued at approximately $2,606,040. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.60% of the company’s stock.

SRPT stock traded up $1.23 during midday trading on Wednesday, reaching $119.70. The stock had a trading volume of 23,023 shares, compared to its average volume of 1,180,875. The company has a debt-to-equity ratio of 0.35, a quick ratio of 11.15 and a current ratio of 12.17. The firm has a market capitalization of $8.75 billion, a P/E ratio of -21.91 and a beta of 1.95. Sarepta Therapeutics Inc has a 52-week low of $94.12 and a 52-week high of $176.50.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.05) by $0.98. The company had revenue of $87.01 million for the quarter, compared to analyst estimates of $86.92 million. Sarepta Therapeutics had a negative return on equity of 36.26% and a negative net margin of 124.66%. On average, equities analysts forecast that Sarepta Therapeutics Inc will post -4.33 earnings per share for the current year.

SRPT has been the topic of a number of research analyst reports. Citigroup lifted their price target on shares of Sarepta Therapeutics from $188.00 to $201.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Nomura lifted their price target on shares of Sarepta Therapeutics from $205.00 to $230.00 and gave the company a “buy” rating in a research note on Thursday, February 28th. JMP Securities reissued a “buy” rating and issued a $270.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, February 27th. Cantor Fitzgerald reissued a “buy” rating on shares of Sarepta Therapeutics in a research note on Friday, February 22nd. Finally, Cowen reissued a “buy” rating and issued a $213.00 price target on shares of Sarepta Therapeutics in a research note on Sunday, March 31st. One analyst has rated the stock with a hold rating, twenty-six have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $199.35.

TRADEMARK VIOLATION NOTICE: This story was originally published by WKRB News and is owned by of WKRB News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.wkrb13.com/2019/06/12/mosaic-family-wealth-llc-has-274000-stake-in-sarepta-therapeutics-inc-nasdaqsrpt.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Article: Asset Allocation

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.